Cosmo Pharmaceuticals Nv · SIX:COPN
Cosmo Pharmaceuticals Nv — FY2022 Earnings Presentation
28 slides from Cosmo Pharmaceuticals Nv's earnings presentation, March 2023
Slide 1: Where we are and where we are going
Where we are and where we are going Full Year Results 2022 Investor Presentation March 2023
Slide 2: Safe harbour
Safe harbour This presentation may include forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that any of its p
Slide 3: 01 Overview 02 Key growth drivers 03 2022 financial review
01 Overview 02 Key growth drivers 03 2022 financial review 04 Key priorities and 2023 guidance 3 Full year results 2022
Slide 4: Overview
01 Overview 4 Full year results 2022
Slide 5: Our product offering
Our product offering Cosmo is the only company its size who can claim 6 approved drugs in its portfolio and 2 approved medical devices in 3 areas Gastrointestinal HealthTech Dermatology Inflammatory Bowel Disease Artificial Intelligence applications Skin (Acne) Colorectal cancer prevention on real t
Slide 6: Progress in 2022
Progress in 2022 GI Genius Cortiment First US study showing 50% reduction in missed Submission of Cortiment’s NDA in Japan colorectal lesions by Ferring Expansion of agreement with Medtronic Medtronic wins US Veterans agreement for 115 devices Named into Fortune 2022 “Change the World” list Eleview
Slide 7: Our legacy business continues to grow
Our legacy business continues to grow Lialda/Mezavant/Mesavancol Uceris/Cortiment Revenue in Eur (Millions) Revenue in Eur (Millions) €29.6m €16.4m Revenue €7.3m €65.5 m €27.8m +13.2% versus 2021 2021 2022 2021 2022 The vast majority of the legacy business is generated by manufacturing of own produc
Slide 8: We have an exciting development pipeline
We have an exciting development pipeline One product entering clinical stage III with high potential CB-03-10 CB-01-33 in the hair loss market (Oncology) (Gastrointestinal) Phase I study started in Formulation & IP Breezula patients with advanced protection completed (Dermatology) refractory solid t
Slide 9: Key growth drivers
02 Key growth drivers 9 Full year results 2022
Slide 10: Winlevi & GI Genius
Our key growth drivers are two revolutionary products performing in large markets with strong partners Winlevi® & GI Genius™ are entrusted to most reputed partners and performing well 10 Full year results 2022
Slide 11: Winlevi the #1 prescribed branded topical acne product in the U.S.
Winlevi the #1 prescribed branded topical acne product in the U.S. Unique prescribers since launch Prescriptions (TRX) generated on a cumulative basis to date ~13,200 (represents 82% of total HCP1 in dermatology) 1HCP: Health Care Providers 50m >530,000 Launched in the U.S. by Patients in US Potenti
Slide 12: Winlevi is one of Sun Pharma's two key growth drivers
Winlevi is one of Sun Pharma’s two key growth drivers “The main driver of growth was the “Ilumya and Winlevi Specialty business, were the key growth driven by Ilumya and drivers for the Winlevi” quarter” Quote from Mr. Abhay Gandhi, CEO (North America Business), Sun Pharmaceutical Industries Ltd. Q3
Slide 13: The uniqueness of GI Genius is the sum of six components
The uniqueness of GI Genius is the sum of six components Science AI Software Data VISION Hardware Certification Regulatory 14 Full year results 2022
Slide 14: GI Genius U.S. installed base continues to grow
GI Genius U.S. installed base continues to grow 08 1,250 Einstein Medical, 01 Beth Israel (BIDMC) Harvard, Boston Pennsylvania 02 Stanford University, California 09 Hospital Corporation of America (HCA) Units installed since launch 03 Cornell University, New York 10 US Veterans Affairs, Virginia 04
Slide 15: GI Genius was one of the growth highlights of Medtronic 3Q
GI Genius was one of the growth highlights of Medtronic 3Q results Medtronic 3Q slide quote Respiratory, Gastrointestinal, & Renal (RGR) “ Patient Monitoring: LSD Nellcor Pilse oximetry growth on tough Y/Y comps; HSD OUS growth Respiratory Interventions: High-20s Gastrointestinal: decline in ventila
Slide 16: GI Genius: where we are
GI Genius: where we are • Already present in 1,250 endoscopy towers • The US market only is 30,000 endoscopy towers • There is nothing else to do, the product is ready • The space we are occuping right now is huge • We are reducing by 50% the miss rate • We are changing the paradigm of the second la
Slide 17: GI Genius: where we are going, pioneering human-AI collaboration
GI Genius: where we are going, pioneering human-AI collaboration We are so advanced in the process that Medtronic GI Genius is a platform with a modular has just released the following release architecture Its purpose is to overlay AI content to any Medtronic to boost AI innovation with new platform
Slide 18: Strategic collaboration with Medtronic designed to accelerate AI innovation
Strategic collaboration with Medtronic designed to accelerate AI innovation in healthcare • GI Genius was designed to host multiple AI algorithms and is suitable for any diagnostic or clinical procedure performed by a physician looking at a screen • We have already created the Innovation Centre Cosm
Slide 19: An opportunity to lead in real-time AI in the US market
An opportunity to lead in real-time AI in the US market 19M 6M 500K 15M Millions of GI Upper Colonoscopy ERCP Laparoscopy procedures endoscopy per year in the Surgical US could benefit from real-time AI 1.6M 1.5M 640K 4M Non-GI analysis Rhinoscopy Cystoscopy Laryngoscopy Arthroscopy 20 Full year res
Slide 20: Economics of SaMD – potential recurring revenue
Economics of SaMD – potential recurring revenue 1,250 units $1,000 /month per AI app Create the leading medical AI platform Accelerate AI innovation $15M $45M $75M $225M $150M $450M Improve patient outcomes ARR 3yr ARR 3yr contract ARR 3yr contract contract 1 app 5 apps 10 apps 21 Full year results
Slide 21: 2022 Financial review
03 2022 Financial review 22 Full year results 2022
Slide 22: Substantial growth in revenue, EBITDA and operating profit
Substantial growth in revenue, EBITDA and operating profit FY22 Revenue FY22 Operating profit €102.1m + 56.9% €28.1m + 153.2% (2021: €65.1m) (2021: €11.1m) FY22 EBITDA Profit after tax €41.9m + 126.5% €24.5m (2021: €18.5m) (2021: €24.0m) 23 Full year results 2022
Slide 23: Positive cashflow from operations, increased cash position, increased stake in treasury shares
Positive cashflow from operations, increased cash position, increased stake in treasury shares FY22 Net cash inflow Treasury shares at market from operations value 31 Dec. 2022 €33.2m €73.6m (2021: €12.6m) (2021: €53.1m) Cash and short-term investments Treasury shares held at 31 Dec. 2022 at 31 Dec.
Slide 24: Our business model is delivering EBITDA
Our business model is delivering • Delivered record revenues in 2022 EBITDA € 41.9m • Profitable • Generating positive cashflows • Legacy business continues to grow • New products delivering substantial revenues • On track to fully capture existing opportunities € 18.5m • Increased dividend distribu
Slide 25: Key priorities, 2023 guidance
04 Key priorities, 2023 guidance 26 Full year results 2022
Slide 26: 2023 Key Priorities
2023 Key Priorities 01 Expand GI Genius business with Medtronic 03 Advance our clinical and development pipeline 02 Expand Winlevi franchise in the RoW 27 Full year results 2022
Slide 27: 2023 Guidance
2023 Guidance 2023 will be Total Revenue characterised by the €110m – €120m performance of our two key growth drivers Operating Profit GI Genius and Winlevi €25m – €35m 28 Full year results 2022
Slide 28: Thank you
Mr. Alessandro Della Chà, CEO Thank you adellacha@cosmopharma.com Mr. Niall Donnelly, CFO Cosmo Pharmaceuticals N.V. ndonnelly@cosmopharma.com Riverside II Sir John Rogerson’s Quay Dublin 2, Ireland Ms. Hazel Winchester, Head of IR hwinchester@cosmopharma.com investor.relations@cosmopharma.com